KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France. PMID 37659907 · Bull Cancer · 2023-Oct The study is a real-world descriptive analysis of an early access program for dostarlimab in endometrial cancer. It is not a randomized controlled trial, does not report a Phase III/IIIb or Phase II/III design, and its primary efficacy outcomes are response rates (ORR, DCR), not time-to-event endpoints like OS or PFS. Therefore, it does not meet the eligibility criteria for a randomized Phase III/IIIb trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations. PMID 37651927 · Lung Cancer · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Surgical quality and prospective quality control of the D2-gastrectomy for gastric cancer in the multicenter randomized LOGICA-trial. PMID 37651889 · Eur J Surg Oncol · 2023-Oct The study is a randomized, multicenter, phase III trial in oncology with results, but the abstract does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) for a drug intervention. The primary focus is surgical quality control and a novel scoring system, with survival mentioned only as a secondary analysis without specific results. Therefore, it does not meet the criteria for inclusion as a drug-intervention efficacy trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. PMID 37647728 · Lung Cancer · 2023-Oct The record is from a Phase Ib trial, which does not meet the inclusion criterion of being a Phase III/IIIb or Phase II/III trial. All other required criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) are met, but the phase criterion is not.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials. PMID 37634702 · J Clin Epidemiol · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. PMID 37597578 · Ann Oncol · 2023-Oct Phase is not explicitly stated as Phase III/IIIb or Phase II/III in the abstract or metadata. The SUMMIT trial is described as a 'basket study' and the abstract reports on a randomized substudy of 21 patients, but the overall trial phase is not defined. The report type is secondary, as it focuses on a specific substudy and includes biomarker analysis, but it does report PFS, a primary/key secondary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers. PMID 37596814 · Clin Transl Sci · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial. PMID 37595489 · Eur J Cancer · 2023-Oct The study is a randomized oncology trial with time-to-event endpoints and a drug intervention (chemotherapy). However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided record, which is a required criterion for eligibility. Metadata signals indicate 'phase3: false'. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients. PMID 37592827 · J Cachexia Sarcopenia Muscle · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized controlled trial in gastric or gastroesophageal junction adenocarcinoma undergoing systemic therapy over two decades. PMID 37591026 · Eur J Surg Oncol · 2023-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Randomized Trial Comparing the Effectiveness of Pre-test Genetic Counseling Using an Artificial Intelligence Automated Chatbot and Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer. PMID 37567976 · Ann Surg Oncol · 2023-Oct The study is an oncology, human, randomized trial reporting original results, but it is not a Phase III/IIIb or II/III trial of a drug-containing intervention with a primary time-to-event efficacy endpoint. The intervention is a genetic counseling service delivery model (AI chatbot vs. counselor), not a drug. The primary endpoints are knowledge scores and patient satisfaction, which are not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. PMID 37562095 · Oral Oncol · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of meaning-centered group psychotherapy in Chinese patients with cancer: A randomized controlled trial. PMID 37558651 · Palliat Support Care · 2023-Oct The study is a randomized controlled trial in oncology (human cancer patients) with original primary results. However, it is excluded because it does not meet key eligibility criteria: 1) The intervention is psychotherapy (non-drug). 2) The endpoints (meaning in life, post-traumatic growth, psychological distress, fear of recurrence) are patient-reported outcomes/quality-of-life measures, not time-to-event efficacy endpoints (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. 3) The phase is not specified as Phase III or a definitive trial; the abstract describes a small randomized trial (n=66) with no phase indicated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. PMID 37555764 · Mol Carcinog · 2023-Oct The record describes a retrospective analysis to develop a predictive scoring system for resistance to a drug combination. While the underlying study is randomized and involves a drug intervention with a time-to-event endpoint, the report itself is not the primary result of a Phase III/IIIb or Phase II/III randomized trial, which is a required eligibility criterion. Phase information is not established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. PMID 37548831 · Int J Clin Oncol · 2023-Oct The record describes a long-term follow-up report of a Phase III randomized trial (CheckMate 227 Part 1) with a primary time-to-event efficacy endpoint (overall survival). The trial phase is confirmed by the trial identifier (NCT02477826, a Phase III trial) and the study design. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study - 1. PMID 37545176 · Acta Radiol · 2023-Oct The report is an original result from a randomized oncology trial (DaRenCa-1) with drug intervention. However, it is a safety analysis focused on late adverse events to iodinated contrast media. While it mentions PFS and OS as secondary comparisons, the primary analysis and conclusion are about safety, not efficacy. Therefore, it does not meet the requirement of having a primary or key secondary time-to-event efficacy endpoint as the main focus of the report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Psychological outcomes of the systematic interventions based on the stress-induced situation, affective, bodily, and cognitive reactions framework for patients with lung cancer: A randomized clinical trial. PMID 37544148 · Int J Nurs Stud · 2023-Oct The study is a randomized, oncology trial with primary results, but it does not meet the eligibility criteria because it lacks a drug-containing intervention and a time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. PMID 37541263 · Lancet Gastroenterol Hepatol · 2023-Oct Study is an original randomized trial in oncology patients, but it lacks a drug intervention and uses a non-time-to-event primary endpoint, making it ineligible for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. PMID 37537253 · Br J Cancer · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. PMID 37517154 · Breast · 2023-Oct The record is a randomized controlled trial of a drug intervention in oncology (breast cancer) with a primary time-to-event efficacy endpoint (mortality). The phase is not explicitly stated in the provided metadata, but the trial design and clinical context are consistent with a Phase III trial, meeting the 'phase3_or_definitive' criterion. All other eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study. PMID 37515369 · Clin Transl Sci · 2023-Oct The record is a prospective multicenter real-life study evaluating pharmacokinetic interactions and clinical facts, not a report of a randomized controlled trial. It does not present time-to-event efficacy endpoints as primary or key secondary outcomes; hematologic outcomes like complete remission and neutropenia duration are reported as descriptive data without Kaplan-Meier or HR analysis.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction: A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT). PMID 37505358 · Ann Surg Oncol · 2023-Oct The record is a correction/erratum for a trial, not an original result report. The empty abstract prevents verification of required criteria like human study and time-to-event endpoint. Therefore, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The MAGIC algorithm probability (MAP)-guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial. PMID 37497879 · Am J Hematol · 2023-Oct The record describes a randomized controlled trial in oncology (HSCT for hematologic malignancy) with a drug intervention and a time-to-event primary endpoint (cumulative incidence, a form of time-to-event). However, the required Phase III/IIIb or Phase II/III evidence is not explicitly confirmed in the provided metadata (title, abstract, publication types, MeSH), leaving the 'phase3_or_definitive' criterion unmet. Therefore, is_eligible is set to false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. PMID 37493665 · Eur J Nucl Med Mol Imaging · 2023-Oct The record describes a primary analysis from a Phase III randomized trial in oncology, but the endpoint is diagnostic validation and correlation, not a time-to-event efficacy outcome for a drug intervention. The abstract does not report OS, PFS, DFS, or other survival metrics, nor Kaplan-Meier curves or hazard ratios. The intervention described is an AI tool for imaging analysis, not a drug therapy. Therefore, it does not meet the inclusion criteria for time-to-event efficacy endpoint and drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study. PMID 37488394 · Ann Surg Oncol · 2023-Oct The record is a retrospective cohort study, not a randomized controlled trial. It does not have a phase III/IIIb or Phase II/III randomized trial design, and it does not involve a drug intervention (it evaluates neoadjuvant chemotherapy vs. no chemotherapy in a retrospective database analysis, but the intervention is not a drug in a controlled trial setting).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. PMID 37480995 · Radiother Oncol · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial. PMID 37480994 · Radiother Oncol · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. PMID 37455214 · Clin Genitourin Cancer · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. PMID 37449716 · ESC Heart Fail · 2023-Oct This is a protocol for a randomized trial in oncology patients, but it is not a report of formal results. The primary endpoint is cardiotoxicity (decrease in LVEF), not a time-to-event efficacy endpoint like OS or PFS. The phase is not explicitly stated as III/IIIb. The intervention targets prevention of treatment side effects, not the efficacy of the cancer treatment itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Feasibility study on individualized management of postoperative patients with differentiated thyroid cancer based on internet and programming technology. PMID 37438541 · J Cancer Res Clin Oncol · 2023-Oct The study is a randomized feasibility study in differentiated thyroid cancer, but it is not a Phase III/IIIb or Phase II/III trial, the experimental intervention is a management mode (mobile app), not a drug intervention, and the primary endpoint is not a time-to-event efficacy endpoint like OS/PFS/DFS etc.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma. PMID 37436513 · J Cancer Res Clin Oncol · 2023-Oct The study is a prognostic biomarker analysis for intrahepatic cholangiocarcinoma using plasma metabolomics. It reports overall survival, which is a time-to-event endpoint, and is an original research article. However, it does not involve a drug-containing intervention; it evaluates a prognostic model based on metabolomic biomarkers. The publication type lists 'Randomized Controlled Trial', but this is for the random split of the cohort into discovery/validation sets, not for a therapeutic intervention. The study is not a Phase III/IIIb or Phase II/III randomized trial of a drug. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study. PMID 37436512 · J Cancer Res Clin Oncol · 2023-Oct Observational registry study; not a randomized controlled trial with a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic nomogram for external ear melanoma patients in the elderly: a SEER-based study. PMID 37434093 · J Cancer Res Clin Oncol · 2023-Oct The study is a retrospective prognostic nomogram analysis using a public database (SEER) to predict survival in elderly external ear melanoma patients. It is not a randomized trial testing a specific drug intervention. Key criteria for eligibility (randomized, phase 3/definitive trial, drug intervention as the tested agent) are not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A practical nomogram and risk stratification system for predicting survival outcomes in neuroblastoma patients: a SEER population-based study. PMID 37430162 · J Cancer Res Clin Oncol · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic nomogram for colorectal cancer patients with multi-organ metastases: a Surveillance, Epidemiology, and End Results program database analysis. PMID 37428251 · J Cancer Res Clin Oncol · 2023-Oct The study is a prognostic nomogram development using a database, not a drug intervention trial, and lacks Phase III/IIIb or Phase II/III randomized trial evidence with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stoma-site approach single-port laparoscopic versus conventional multi-port laparoscopic Miles's procedure for low rectal cancer: A prospective, randomized controlled trial. PMID 37422394 · Asian J Surg · 2023-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Construction and validation of a nomogram for hepatocellular carcinoma patients based on HCC-GRIm score. PMID 37421461 · J Cancer Res Clin Oncol · 2023-Oct The study is a retrospective prognostic nomogram analysis for hepatocellular carcinoma, not a randomized trial. While it involves time-to-event outcomes (survival prognosis, C-index, time-dependent AUC), it does not meet the core eligibility criteria: it is not randomized, is not a Phase III/IIIb or Phase II/III trial, and lacks a drug-containing intervention. The publication type 'Randomized Controlled Trial' is inaccurate; the methods describe a retrospective cohort split into training/validation sets, not randomization to treatment arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Web-based nomogram and risk stratification system constructed for predicting the overall survival of older adults with primary kidney cancer after surgical resection. PMID 37410141 · J Cancer Res Clin Oncol · 2023-Oct The study is an oncology analysis of surgical outcomes in elderly kidney cancer patients using the SEER database. While it involves human subjects, randomized data partitioning, and a time-to-event endpoint (OS), it lacks a drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial of a drug. The 'Randomized Controlled Trial' publication type likely refers to the random splitting of the dataset for model validation, not a drug intervention trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Web-based nomograms for predicting overall survival and cancer-specific survival in retroperitoneal leiomyosarcoma: a population-based analysis. PMID 37405479 · J Cancer Res Clin Oncol · 2023-Oct The record is an oncology study of human patients with retroperitoneal leiomyosarcoma reporting time-to-event outcomes (OS and CSS). However, it is a retrospective cohort analysis from the SEER database focused on developing prognostic nomograms, not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The 'randomized' flag in metadata refers to the random split of the cohort for training/validation, not randomization to treatment arms. There is no drug intervention. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort of drug trial results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic nomogram for glioblastoma (GBM) patients presenting with distant extension: a seer-based study. PMID 37401940 · J Cancer Res Clin Oncol · 2023-Oct The record describes a retrospective, SEER-based prognostic nomogram study for glioblastoma. While the abstract mentions 'randomized' in the context of splitting data into training/validation cohorts and the publication type includes 'Randomized Controlled Trial', the study itself is not a randomized clinical trial of a drug intervention. It is a secondary analysis/model-building study using existing data. Therefore, it does not meet the core eligibility criteria of being an original result report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells. PMID 37395846 · J Cancer Res Clin Oncol · 2023-Oct The study is an original prognostic model development and validation paper using data from patients who received CAR-T cell therapy, not a report of a randomized drug trial. While it includes randomized subjects and time-to-event endpoints, it is not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as the primary comparison. The 'drug_intervention' criterion is not met as CAR-T is a cellular therapy and the study's primary aim is model development, not trial results. The publication type 'Randomized Controlled Trial' refers to the internal data split, not the study design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study. PMID 37392201 · J Cancer Res Clin Oncol · 2023-Oct Study meets all eligibility criteria: oncology (gastric cancer), human, randomized, phase III/definitive, drug intervention (chemotherapy regimens), time-to-event efficacy endpoint (DFS, OS), and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 2 Figure · 2 Panel · risk not_visible
Three-Field Versus Two-Field Lymphadenectomy in Minimally Invasive Esophagectomy: 3-Year Survival Outcomes of a Randomized Trial. PMID 37358684 · Ann Surg Oncol · 2023-Oct The study is a randomized controlled trial reporting overall survival and disease-free survival (time-to-event endpoints) for esophageal cancer, a human malignancy. However, the intervention is purely surgical (lymphadenectomy extent) with no drug component, and the trial phase is not specified as Phase III or definitive. Therefore, it fails the drug intervention and phase criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial. PMID 37347393 · Qual Life Res · 2023-Oct The study is a Phase III randomized trial with a drug intervention in oncology, but it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). It is a psychometric/quality-of-life analysis of a patient-reported outcome tool.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised controlled trial testing acceptance of practitioner-referral versus self-referral to stop smoking services within the Lung Screen Uptake Trial. PMID 37331722 · Addiction · 2023-Oct The study is a randomized, human, oncology-related (lung cancer screening/smoking cessation) trial, but it is excluded because (1) the intervention (smoking cessation referral) is not a drug-containing intervention, (2) the primary endpoint (acceptance of referral) is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.), and (3) the comparator is also a non-drug intervention (self-referral vs. practitioner-referral). It does not meet the core requirement for a drug intervention and a time-to-event endpoint in a Phase II/III or III/IIIb randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic Central Neck Dissection Based on Preoperative Imaging and Intraoperative Surgeon's Palpation Versus Total Thyroidectomy Alone for Papillary Thyroid Cancer. PMID 37263083 · J Surg Res · 2023-Oct The study is a randomized surgical trial for thyroid cancer comparing total thyroidectomy with/without prophylactic central neck dissection. It is oncology and human but lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is locoregional recurrence (binary at 5 years), not a time-to-event analysis. It is also not a Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. PMID 37246287 · Hematol Oncol · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs. PMID 37236862 · Clin Genitourin Cancer · 2023-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immediately or delayed sinus augmentation after pseudocyst removal: A randomized trial. PMID 37218035 · Clin Implant Dent Relat Res · 2023-Oct 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome. PMID 37119510 · Fam Cancer · 2023-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -